1. Helicobacter pylori resistance in the Russian Federation: a meta-analysis of studies over the past 10 years
- Author
-
D. N. Andreev, I. V. Maev, and Yu. A. Kucheryavyy
- Subjects
helicobacter pylori ,eradication therapy ,resistance ,sensitivity ,antibacterial drugs ,clarithromycin ,metronidazole ,amoxicillin ,levofloxacin ,tetracycline ,Medicine - Abstract
Aim. Systematization of data on antibiotic resistance of Helicobacter pylori in Russia over the past 10 years. Methods. A search for studies were carried out in electronic databases MEDLINE/PubMed, EMBASE, Cochrane, Russian Science Citation Index. We analyzed the papers published over the past 10 years (2011 to 2020). In the final analysis, publications were selected from periodical peer-reviewed foreign and Russian publications, in which validated tests for assessing the microorganism resistance were used with detailed descriptive statistics, which allows the obtained data to be included in the meta-analysis. Results. The final analysis included 11 studies (808 isolates). H. pylori resistance to clarithromycin was 10.39% (95% confidence interval CI 7.10314.219), metronidazole 33.95% (95% CI 15.32955.639), amoxicillin 1.35% (95% CI 0.281 3.202), levofloxacin 20.0% (95% CI 12.63728.574), tetracycline 0.98% (95% CI 0.3532.163). Double clarithromycin-metronidazole resistance was reported in 2.7% (95% CI 1.1364.345). Conclusion. This meta-analysis is the first analytical work that allows objectifying the current structure of H. pylori antibiotic resistance in the Russian Federation. The data obtained in the analysis of publications over the past 10 years indicate a low resistance of the microorganism to clarithromycin (less than the regulated threshold of 15%), which allows us to consider the triple regimen of eradication therapy as a first-line therapy in our country.
- Published
- 2020